| 1. |
- Olsson-Strömberg, Ulla, et al.
(author)
-
Successful mobilization of Ph-negative blood stem cells with intensive chemotherapy + G-CSF in patients with chronic myelogenous leukemia in first chronic phase
- 2006
-
In: Leukemia and Lymphoma. - : Informa UK Limited. - 1042-8194 .- 1029-2403. ; 47:9, s. 1768-73
-
Journal article (peer-reviewed)abstract
- The aim of the study was to investigate the feasibility of mobilizing Philadelphia chromosome negative (Ph-) blood stem cells (BSC) with intensive chemotherapy and lenograstim (G-CSF) in patients with CML in first chronic phase (CP1). During 1994-1999 12 centers included 37 patients <56 years. All patients received 6 months' IFN, stopping at median 36 (1-290) days prior to the mobilization chemotherapy. All received one cycle of daunorubicin 50 mg/m2 and 1 hour infusion on days 1-3, and cytarabine (ara-C) 200 mg/m2 24 hours' i.v. infusion on days 1-7 (DA) followed by G-CSF 526 microg s.c. once daily from day 8 after the start of chemotherapy. Leukaphereses were initiated when the number of CD 34+ cells was >5/microl blood. Patients mobilizing poorly could receive a 4-day cycle of chemotherapy with mitoxantrone 12 mg/m2/day and 1 hour i.v infusion, etoposide 100 mg/m2/day and 1 hour i.v. infusion and ara-C 1 g/m2/twice a day with 2 hours' i.v infusion (MEA) or a second DA, followed by G-CSF 526 microg s.c once daily from day 8 after the start of chemotherapy. Twenty-seven patients received one cycle of chemotherapy and G-CSF, whereas 10 were mobilized twice. Twenty-three patients (62%) were successfully (MNC >3.5 x 10(8)/kg, CFU-GM >1.0 x 10(4)/kg, CD34+ cells >2.0 x 10(6)/kg and no Ph+ cells in the apheresis product) [n = 16] or partially successfully (as defined above but 1-34% Ph+ cells in the apheresis product) [n = 7] mobilized. There was no mortality during the mobilization procedure. Twenty-one/23 patients subsequently underwent auto-SCT. The time with PMN <0.5 x 10(9)/l was 10 (range 7-49) and with platelets <20 x 10(9)/l was also 10 (2-173) days. There was no transplant related mortality. The estimated 5-year overall survival after auto-SCT was 68% (95% CI 47 - 90%), with a median follow-up time of 5.2 years.We conclude that in a significant proportion of patients with CML in CP 1, intensive chemotherapy combined with G-CSF mobilizes Ph- BSC sufficient for use in auto-SCT.
|
|
| 2. |
|
|
| 3. |
|
|
| 4. |
- Simonsson, Bengt, et al.
(author)
-
Intensive treatment and stem cell transplantation in chronic myelogenous leukemia : long-term follow-up
- 2005
-
In: Acta Haematologica. - : S. Karger AG. - 0001-5792 .- 1421-9662. ; 113:3, s. 155-162
-
Journal article (peer-reviewed)abstract
- In the present study we combined interferon (IFN) and hydroxyurea (HU) treatment, intensive chemotherapy and autologous stem cell transplantation (SCT) in newly diagnosed chronic myelogenous leukemia patients aged below 56 years, not eligible for allogeneic SCT. Patients who had an HLA-identical sibling donor and no contraindication went for an allogeneic SCT (related donor, RD). After diagnosis, patients not allotransplanted received HU and IFN to keep WBC and platelet counts low. After 6 months patients with Ph-positive cells still present in the bone marrow received 1–3 courses of intensive chemotherapy. Those who became Ph-negative after IFN + HU or after 1–3 chemotherapy courses underwent autologous SCT. Some patients with poor cytogenetic response were allotransplanted with an unrelated donor (URD). IFN + HU reduced the percentage of Ph-positive metaphases in 56% of patients, and 1 patient became Ph-negative. After one or two intensive cytotherapies 86 and 88% had a Ph reduction, and 34 and 40% became Ph-negative, respectively. In patients receiving a third intensive chemotherapy 92% achieved a Ph reduction and 8% became Ph-negative. The median survival after auto-SCT (n = 46) was 7.5 years. The chance of remaining Ph-negative for up to 10 years after autologous SCT was around 20%. The overall survival for allo-SCT RD (n = 91) and URD (n = 28) was almost the same, i.e. ≈60% at 10 years. The median survival for all 251 patients registered was 8 years (historical controls 3.5 years). The role of the treatment schedule presented in the imatinib era is discussed.
|
|
| 5. |
- Buono, Benedetto, et al.
(author)
-
Modeling and Characterization of the ON-Resistance in 4H-SiC Power BJTs
- 2011
-
In: IEEE Transactions on Electron Devices. - 0018-9383 .- 1557-9646. ; 58:7, s. 2081-2087
-
Journal article (peer-reviewed)abstract
- The ON-resistance of silicon carbide bipolar transistors is characterized and simulated. Output characteristics are compared at different base currents and different temperatures in order to validate the physical model parameters. A good agreement is obtained, and the key factors, which limit the improvement of R-ON, are identified. Surface recombination and material quality play an important role in improving device performances, but the device design is also crucial. Based on simulation results, a design that can enhance the conductivity modulation in the lowly doped drift region is proposed. By increasing the base doping in the extrinsic region, it is possible to meet the requirements of having low voltage drop, high current density, and satisfactory forced current gain. According to simulation results, if the doping is 5 x 10(18) cm(-3), it is possible to conduct 200 A/cm(2) at V-CE = 1 V by having a forced current gain of about 8, which represents a large improvement, compared with the simulated value of only one in the standard design.
|
|
| 6. |
- Capriata, Corrado Carlo Maria, et al.
(author)
-
Grain structure influence on synchronized two-dimensional spin-Hall nano-oscillators
- 2023
-
In: AIP Advances. - : AIP Publishing. - 2158-3226. ; 13:5
-
Journal article (peer-reviewed)abstract
- Nanoconstriction spin-Hall nano-oscillators (NC-SHNOs) are excellent devices for a wide variety of applications, from RF communication to bio-inspired computing. NC-SHNOs are easy to fabricate in large arrays, are CMOS compatible, and feature a narrow linewidth and high output power. However, in order to take full advantage of the device capabilities, a systematic analysis of the array behavior with respect to the number and dimensions of oscillators, the temperature of operation, and the influence of layer quality is needed. Here, we focus on micromagnetic simulations of 2 x 2 and 4 x 4 NC-SHNO arrays with single oscillators separated by up to 300 nm. We observe a synchronization scheme that allows for column-wise selection of the oscillation frequency for a larger pitch. However, for smaller pitches, a coherent oscillation volume was observed, and this volume included both the constrictions and extended beyond that region. A local variation in the exchange coupling in the active oscillator region was investigated by placing physical grains in the free magnetic layer, and it was shown to influence both the stable current range and the resulting frequency and output power. De-coupling the oscillators along rows or columns could provide higher power due to more favorable phase shifts between oscillators. Our investigation helps in achieving a deeper understanding of the intrinsic working principles of NC-SHNO arrays and how they reach fully synchronized states, and this will help to expand non-conventional computing capabilities.
|
|
| 7. |
- Hedayati, Raheleh, et al.
(author)
-
A 500 degrees C 8-b Digital-to-Analog Converter in Silicon Carbide Bipolar Technology
- 2016
-
In: IEEE Transactions on Electron Devices. - : Institute of Electrical and Electronics Engineers (IEEE). - 0018-9383 .- 1557-9646. ; 63:9, s. 3445-3450
-
Journal article (peer-reviewed)abstract
- High-temperature integrated circuits provide important sensing and controlling functionality in extreme environments. Silicon carbide bipolar technology can operate beyond 500 degrees C and has shown stable operation in both digital and analog circuit applications. This paper demonstrates an 8-b digital-to-analog converter (DAC). The DAC is realized in a current steering R-2R configuration. High-gain Darlington current switches are used to ensure ideal switching at 500 degrees C. The measured differential nonlinearity (DNL) and integral nonlinearity (INL) at 25 degrees C are 0.79 and 1.01 LSB, respectively, while at 500 degrees C, the DNL and INL are 4.7 and 2.5 LSB, respectively. In addition, the DAC achieves 53.6 and 40.6 dBc of spurious free dynamic range at 25 degrees C and 500 degrees C, respectively.
|
|
| 8. |
- Hedayati, Raheleh, et al.
(author)
-
A Monolithic, 500 degrees C Operational Amplifier in 4H-SiC Bipolar Technology
- 2014
-
In: IEEE Electron Device Letters. - : IEEE. - 0741-3106 .- 1558-0563. ; 35:7, s. 693-695
-
Journal article (peer-reviewed)abstract
- A monolithic bipolar operational amplifier (opamp) fabricated in 4H-SiC technology is presented. The opamp has been used in an inverting negative feedback amplifier configuration. Wide temperature operation of the amplifier is demonstrated from 25 degrees C to 500 degrees C. The measured closed loop gain is around 40 dB for all temperatures whereas the 3 dB bandwidth increases from 270 kHz at 25 degrees C to 410 kHz at 500 degrees C. The opamp achieves 1.46 V/mu s slew rate and 0.25% total harmonic distortion. This is the first report on high temperature operation of a fully integrated SiC bipolar opamp which demonstrates the feasibility of this technology for high temperature analog integrated circuits.
|
|
| 9. |
|
|
| 10. |
- Johansson, Bertil, et al.
(author)
-
Cytogenetic polyclonality in hematologic malignancies
- 1999
-
In: Genes, Chromosomes and Cancer. - 1045-2257. ; 24:3, s. 222-229
-
Journal article (peer-reviewed)abstract
- The present study was undertaken to ascertain the frequency of cytogenetic polyclonality in various hematologic malignancies and to investigate whether morphologic subgroup, age, gender, or previous genotoxic exposure influences the incidence. Among 2,243 cytogenetically investigated hematologic malignancies, 10 acute myeloid leukemias (AML), 5 myelodysplastic syndromes (MDS), 2 acute lymphoblastic leukemias (ALL), 1 acute undifferentiated leukemia (AUL), 1 atypical Philadelphia chromosome-negative (Ph-) chronic myeloid leukemia (CML), 1 chronic myeloproliferative disorder (CMD), and 1 chronic lymphoproliferative disorder (CLD) with karyotypically unrelated clones were identified, constituting 2.6% of AML, 1.6% of MDS, 0.8% of ALL, 13% of AUL, 9.1% of Ph- CML, 1.5% of CMD, and 2.8% of CLD with chromosomal abnormalities. In contrast to the cytogenetic features, the X-inactivation pattern was monoclonal in the two informative female patients that could be investigated. Among 17,733 karyotypically aberrant published cases surveyed, significant frequency differences (P < 0.001) were discerned: 1.7% of 6,526 AML, 3.4% of 2,391 MDS, 0.4% of 1,920 Ph+ CML, 2.9% of 856 CMD, 0.9% of 4,226 ALL, and 5.8% of 1,814 CLD displayed unrelated clones. The incidence of cytogenetic polyclonality did not differ significantly among the MDS, CMD, or ALL subgroups, between males and females, between children (< 16 years) and adults, or between B- and T-cell ALL, whereas the frequencies varied among the AML FAB types (P < 0.05), among the different CLD entities (P < 0.001), and between B- and T-cell CLD (P < 0.001). Furthermore, the incidence was higher in therapy-related AML and MDS than in de novo AML and MDS (P < 0.001 and P < 0.01, respectively).
|
|
